Showing 2 posts of 2 posts found.


Astellas Pharma and BMT CTN announce phase 3 data for gilteritinib

June 9, 2023
Research and Development Astellas Pharma, BMT CTN, Haematology, gilteritinib, leukaemia, pharmaceutical

Japanese pharmaceutical company Astellas Pharma and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) have presented their phase …

Gilteritinib becomes first NICE-approved oral therapy for relapsed or refractory acute myeloid leukaemia

July 16, 2020
Sales and Marketing Atellas, NICE, UK, acute myeloid leukaemia, gilteritinib

NICE has revealed its recommendation of Astellas’ gilteritinib for routine use as a monotherapy on the NHS in England and …

Latest content